Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts
Authors
Keywords
-
Journal
Current Oncology Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-19
DOI
10.1007/s11912-023-01461-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients
- (2023) Thomas Gerald et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Prognostic Value of Bladder Involvement in the Outcome of Upper Tract Urothelial Carcinoma
- (2023) Sara Meireles et al. Diagnostics
- READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC).
- (2023) Lorenzo Antonuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
- (2023) Yohann Loriot et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.
- (2022) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
- (2022) Arlene O Siefker-Radtke et al. LANCET ONCOLOGY
- The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives
- (2022) Giorgio Patelli et al. CANCER TREATMENT REVIEWS
- Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care?
- (2022) Brian M. Russell et al. DRUGS & AGING
- Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma
- (2022) Vinay Mathew Thomas et al. Expert Review of Anticancer Therapy
- Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma
- (2022) Charlene M. Mantia et al. Expert Review of Anticancer Therapy
- Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations
- (2022) Andrea Franza et al. Future Oncology
- Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin
- (2022) Mario E Lacouture et al. ONCOLOGIST
- Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy
- (2022) Vivek Nimgaonkar et al. JAMA Oncology
- Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer
- (2022) Jonathan Thomas et al. Cancers
- Metastasis-Directed Radiation Therapy with Consolidative Intent for Oligometastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
- (2022) Nicola Longo et al. Cancers
- First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
- (2022) Roberto R. Iacovelli et al. ANNALS OF ONCOLOGY
- An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next
- (2022) Alberto D’Angelo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC).
- (2022) Shilpa Gupta et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN Bladder 100.
- (2022) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
- (2022) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.
- (2022) Begoña Pérez-Valderrama et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review
- (2022) Tiago Costa de Padua et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure
- (2022) Shinkyo Yoon et al. EUROPEAN JOURNAL OF CANCER
- Enfortumab vedotin in the treatment of urothelial cancers and beyond
- (2022) Risa L Wong et al. Future Oncology
- Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
- (2022) Christopher J. Hoimes et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma
- (2022) Nicolas Sayegh et al. OncoTargets and Therapy
- HER2 expression in urothelial carcinoma, a systematic literature review
- (2022) Emilie Scherrer et al. Frontiers in Oncology
- Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy
- (2022) Kunal K. Sindhu et al. Biomedicines
- Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
- (2022) A.V. Balar et al. ANNALS OF ONCOLOGY
- Platinum-Free Systemic Therapy in First-Line Metastatic Urothelial Carcinoma: Mirage or Oasis in the Platinum Desert?
- (2022) Elizabeth R. Plimack et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma
- (2022) Andrew B. Katims et al. Cancers
- Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
- (2021) Gillian Vandekerkhove et al. Nature Communications
- Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis
- (2021) Alessandro Rizzo et al. European Urology Focus
- Palliative radiotherapy for bladder cancer: a systematic review and meta-analysis
- (2021) Jeremy Tey et al. ACTA ONCOLOGICA
- Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.
- (2021) Yohann Loriot et al. JOURNAL OF CLINICAL ONCOLOGY
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
- (2021) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era
- (2021) Sara Cherri et al. Cancers
- Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer
- (2021) Zhao Zhang et al. BMC CANCER
- Advances in the management of urothelial carcinoma: is immunotherapy the answer?
- (2021) Ariana L. Santopietro et al. EXPERT OPINION ON PHARMACOTHERAPY
- TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
- (2021) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
- (2021) Evan Y Yu et al. LANCET ONCOLOGY
- Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice
- (2021) Petros Grivas et al. CANCER TREATMENT REVIEWS
- Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum‐Based Chemotherapy for Metastatic Disease
- (2021) Risa L. Wong et al. ONCOLOGIST
- Metastasis-directed radiation therapy after radical cystectomy for bladder cancer
- (2021) Andre F. Miranda et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
- (2021) Anuhya Kommalapati et al. Cancers
- The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer
- (2021) Kirollos S Hanna et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
- (2021) Vadim S. Koshkin et al. CANCER
- The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
- (2021) Richard Cathomas et al. EUROPEAN UROLOGY
- Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review
- (2020) Thomas van Doeveren et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275
- (2020) Matthew D. Galsky et al. CLINICAL CANCER RESEARCH
- Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies
- (2020) C. Franzese et al. CLINICAL ONCOLOGY
- Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis
- (2020) Haoran Liu et al. DISEASE MARKERS
- European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update
- (2020) Morgan Rouprêt et al. EUROPEAN UROLOGY
- Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
- (2020) Jacqueline Vuky et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastasectomy of oligometastatic urothelial cancer: a single-center experience
- (2020) Tim Muilwijk et al. Translational Andrology and Urology
- Unifying Themes in Urothelial Cancers
- (2020) John D. Chester EUROPEAN UROLOGY
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder
- (2020) Sandra van Wilpe et al. Cancers
- Enfortumab vedotin – next game-changer in urothelial cancer
- (2020) Moritz Maas et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors
- (2020) Maria-Carlota Londoño et al. Cancers
- Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma
- (2019) Nora Sundahl et al. EUROPEAN UROLOGY
- Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract
- (2019) Cora N. Sternberg et al. EUROPEAN UROLOGY
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
- (2019) Y Fradet et al. ANNALS OF ONCOLOGY
- Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go
- (2019) Thomas Gevaert et al. Future Oncology
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
- (2019) Thomas Powles et al. CANCER TREATMENT REVIEWS
- Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
- (2018) Karen Kelly et al. CANCER
- The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review
- (2018) Mohammad Abufaraj et al. EUROPEAN UROLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Update on the Treatment of Metastatic Urothelial Carcinoma
- (2018) Nedal Bukhari et al. TheScientificWorldJOURNAL
- Update on the Treatment of Metastatic Urothelial Carcinoma
- (2018) Nedal Bukhari et al. Scientific World Journal
- Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series
- (2018) Alessandro Leonetti et al. INTERNATIONAL JOURNAL OF UROLOGY
- Epidemiology of urothelial carcinoma
- (2017) Jun Miyazaki et al. INTERNATIONAL JOURNAL OF UROLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Can urologists introduce the concept of “oligometastasis” for metastatic bladder cancer after total cystectomy?
- (2017) Koichiro Ogihara et al. Oncotarget
- Urothelial carcinoma management in elderly or unfit patients
- (2016) Joaquim Bellmunt et al. EJC SUPPLEMENTS
- The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks
- (2016) Marcus G. Cumberbatch et al. EUROPEAN UROLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Experience of multidisciplinary assessment of elderly patients with cancer in a French general hospital during 1year: A new model care study
- (2013) V. Bouzereau et al. Journal of Geriatric Oncology
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
- (2012) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
- (2011) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
- (2011) Maria De Santis et al. JOURNAL OF CLINICAL ONCOLOGY
- A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
- (2011) Matthew D Galsky et al. LANCET ONCOLOGY
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
- (2009) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search